These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

893 related items for PubMed ID: 9205822

  • 1. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE, Ahern D, Scatina J, Kao J.
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [Abstract] [Full Text] [Related]

  • 2. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L, Riesenman C, Lam YW.
    Clin Pharmacokinet; 1995 Jun; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [Abstract] [Full Text] [Related]

  • 3. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
    Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE.
    Br J Clin Pharmacol; 1992 Sep; 34(3):262-5. PubMed ID: 1389951
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
    Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Shader RI.
    Br J Clin Pharmacol; 1997 Nov; 44(5):495-8. PubMed ID: 9384467
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
    von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI.
    J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
    [Abstract] [Full Text] [Related]

  • 6. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal.
    Riesenman C.
    Pharmacotherapy; 1995 Apr; 15(6 Pt 2):84S-99S. PubMed ID: 8587855
    [Abstract] [Full Text] [Related]

  • 7. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ.
    Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
    [Abstract] [Full Text] [Related]

  • 8. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
    Danie WA, Syrek M, Ryłko Z, Wójcikowski J.
    Pol J Pharmacol; 2001 Nov; 53(4):351-7. PubMed ID: 11990081
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
    Hemeryck A, De Vriendt C, Belpaire FM.
    Eur J Clin Pharmacol; 1999 Feb; 54(12):947-51. PubMed ID: 10192756
    [Abstract] [Full Text] [Related]

  • 10. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT.
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [Abstract] [Full Text] [Related]

  • 11. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
    McKillop D, Wild MJ, Butters CJ, Simcock C.
    Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW, Dyroff MC.
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [Abstract] [Full Text] [Related]

  • 13. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K.
    Eur J Clin Pharmacol; 1996 May; 51(1):73-8. PubMed ID: 8880055
    [Abstract] [Full Text] [Related]

  • 14. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
    Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brøsen K.
    Eur J Clin Pharmacol; 1998 May; 54(3):261-4. PubMed ID: 9681670
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
    Murray S, Odupitan AO, Murray BP, Boobis AR, Edwards RJ.
    Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
    [Abstract] [Full Text] [Related]

  • 16. Inhibitors of imipramine metabolism by human liver microsomes.
    Skjelbo E, Brøsen K.
    Br J Clin Pharmacol; 1992 Sep; 34(3):256-61. PubMed ID: 1389950
    [Abstract] [Full Text] [Related]

  • 17. Reducing the risk of drug-drug interactions: a goal of rational drug development.
    Preskorn SH.
    J Clin Psychiatry; 1996 Sep; 57 Suppl 1():3-6. PubMed ID: 8617709
    [No Abstract] [Full Text] [Related]

  • 18. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL, Payne NA, Wienkers LC, Hauer MJ, Sanders PE.
    Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
    Nelson MH, Birnbaum AK, Remmel RP.
    Epilepsy Res; 2001 Apr; 44(1):71-82. PubMed ID: 11255075
    [Abstract] [Full Text] [Related]

  • 20. Drug-drug interactions.
    Preskorn SH.
    J Clin Psychiatry; 1996 May; 57(5):223-7. PubMed ID: 8626354
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.